跳转至内容
Merck
CN

D9305

1-Deoxynojirimycin hydrochloride

别名:

1,5-Dideoxy-1,5-imino-D-sorbitol hydrochloride

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C6H13NO4 · HCl
化学文摘社编号:
分子量:
199.63
UNSPSC Code:
12352201
NACRES:
NA.32
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
3563225
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


assay

≥98% (TLC)

Quality Level

form

powder

solubility

water: 19.60-20.40 mg/mL, clear, colorless

antibiotic activity spectrum

viruses

mode of action

enzyme | inhibits

storage temp.

2-8°C

SMILES string

Cl[H].OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O

InChI

1S/C6H13NO4.ClH/c8-2-3-5(10)6(11)4(9)1-7-3;/h3-11H,1-2H2;1H/t3-,4+,5-,6-;/m1./s1

InChI key

ZJIHMALTJRDNQI-VFQQELCFSA-N

Gene Information

human ... GAA(2548)

General description

Chemical structure: glucosamine

Application

1-Deoxynojirimycin hydrochloride has been used
  • to study its effects on the loss-of-function of N-glycosylation pathway on hair cell regeneration
  • as an endoplasmic reticulum (ER) α-glucosidase I and II inhibitor to study its effects on TMED3-cystic fibrosis transmembrane conductance regulator (CFTR) interaction
  • as an insect trehalase inhibitor in TREH inhibition bioassay

Biochem/physiol Actions

α-Glucosidase inhibitor
1-Deoxynojirimycin (DNJ) is a naturally occurring alkaloid azasugar or iminosugar. It is observed in mulberry leaves, Commelina communis, and bacterial strains including Bacillus and Streptomyces species. DNJ acts as an α-glucosidase inhibitor and exhibits anti-viral anti-diabetic, anti-inflammatory, anti-obesity, and antioxidant properties.


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Marc C Patterson et al.
Orphanet journal of rare diseases, 8, 12-12 (2013-01-18)
Niemann-Pick disease type C (NP-C) is a rare neurovisceral disease characterized by progressive neurodegeneration and premature death. We report data recorded at enrolment in an ongoing international NP-C registry initiated in September 2009 to describe disease natural history, clinical course
Rosemarie E Venier et al.
Journal of medical genetics, 49(9), 591-597 (2012-08-16)
A viable treatment for lysosomal storage disease has been very difficult to attain. One option is pharmacological inhibition of synthetic pathways to reduce substrate accumulations. Miglustat N-butyldeoxynojirimycin (NBDNJ), an inhibitor of glucosylceramide synthase, has shown much promise in clinical trials
Timothy M Cox et al.
Orphanet journal of rare diseases, 7, 102-102 (2012-12-29)
Previous studies have provided equivocal data on the use of miglustat as maintenance therapy in Gaucher disease type 1. We report findings from a clinical trial evaluating the effects of miglustat treatment in patients with stable type 1 Gaucher disease



全球贸易项目编号

货号GTIN
D9305-10MG04061833590607
D9305-5MG04061833590614